Literature DB >> 32745803

The emerging role of lncRNAs in multiple sclerosis.

Samin Ghaderian1, Navid Shomali2, Soheil Behravesh1, Gholamreza Rezaei Danbaran1, Maryam Hemmatzadeh2, Saeed Aslani3, Farhad Jadidi-Niaragh4, Ramin Hosseinzadeh3, Shahram Torkamandi5, Hamed Mohammadi6.   

Abstract

Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS) with various clinical manifestations. The characteristic of MS is that myelin is attacked by the body's immune system and increases the electrical capacity of axons, and is the primary pathophysiological mechanism of the transmission block. Studies have shown that epigenetic factors participate in the development of MS. LncRNAs are highly abundant and heterogeneous linear RNA transcripts with lengths exceeding 200 nucleotides and no protein-coding potential. Currently, pieces of evidence have demonstrated that lncRNAs have fundamental actions in multiple cellular pathways, including immune system regulation, epithelial-mesenchymal transition (EMT), cancer cell growth and metastasis, cellular homeostasis, and embryo development. It has been demonstrated that epigenetic mechanisms have an abundant role in the pathogenesis of MS in which the role of lncRNAs as epigenetic regulatory molecules in molecular processes has been proven. In this paper, we have focused on the correlation between MS and lncRNAs, the role of lncRNA in the pathogenesis of the disease, and the diagnostic and prognostic potential of lncRNA in MS.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune diseases; Demyelination; LncRNA; Multiple sclerosis

Mesh:

Substances:

Year:  2020        PMID: 32745803     DOI: 10.1016/j.jneuroim.2020.577347

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Dysregulation of long noncoding RNA MEG3 and NLRC5 expressions in patients with relapsing-remitting multiple sclerosis: is there any correlation?

Authors:  Shahram Torkamandi; Shima Bahrami; Tahereh Ghorashi; Mohammad Dehani; Hadi Bayat; Seyyed Mohamad Hoseini; Somaye Rezaei; Mohsen Soosanabadi
Journal:  Genes Immun       Date:  2021-11-15       Impact factor: 2.676

Review 2.  Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.

Authors:  Hussein Baharlooi; Amir Hossein Mansourabadi; Moein Minbashi Moeini; Leila Mohamed Khosroshahi; Maryam Azimi
Journal:  Cell Mol Neurobiol       Date:  2021-10-25       Impact factor: 4.231

Review 3.  Biomarkers in Rare Demyelinating Disease of the Central Nervous System.

Authors:  Marina Boziki; Styliani-Aggeliki Sintila; Panagiotis Ioannidis; Nikolaos Grigoriadis
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

4.  Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis.

Authors:  Sherein G Elgendy; Rawan Abd-Elhameed; Enas Daef; Shereen M Mohammed; Hebatallah M Hassan; Mohamed A El-Mokhtar; Ahmed Nasreldein; Eman M Khedr
Journal:  Iran J Microbiol       Date:  2021-10

5.  Identification of Novel Key Genes and Pathways in Multiple Sclerosis Based on Weighted Gene Coexpression Network Analysis and Long Noncoding RNA-Associated Competing Endogenous RNA Network.

Authors:  Yuehan Hao; Miao He; Yu Fu; Chenyang Zhao; Shuang Xiong; Xiaoxue Xu
Journal:  Oxid Med Cell Longev       Date:  2022-03-02       Impact factor: 6.543

Review 6.  Long Intergenic Noncoding RNAs Affect Biological Pathways Underlying Autoimmune and Neurodegenerative Disorders.

Authors:  Patrycja Plewka; Katarzyna Dorota Raczynska
Journal:  Mol Neurobiol       Date:  2022-07-07       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.